share_log

藥明康德:翌日披露報表

WUXI APPTEC: Next Day Disclosure Return

香港交易所 ·  Mar 26 06:14
Summary by Moomoo AI
無錫藥明康德新藥開發股份有限公司於2024年3月8日至26日期間,通過上海證券交易所回購共計3,359,666股A股普通股,佔公司已發行股份的約0.13%。該公司股份回購的價格範圍在RMB 47.5至RMB 57.32之間,並於2024年3月26日以RMB 20,045,895的總金額回購了422,000股。此外,同日公司亦根據2019年A股激勵計劃行使股票期權,發行了29,747股A股普通股。股份回購及期權行使後,公司於2024年3月26日的已發行股份總數為2,546,239,690股。根據香港聯合交易所有限公司證券上市規則,公司已完成相關披露要求,並確認所有交易均獲董事會批准,並符合相關法律規定。
無錫藥明康德新藥開發股份有限公司於2024年3月8日至26日期間,通過上海證券交易所回購共計3,359,666股A股普通股,佔公司已發行股份的約0.13%。該公司股份回購的價格範圍在RMB 47.5至RMB 57.32之間,並於2024年3月26日以RMB 20,045,895的總金額回購了422,000股。此外,同日公司亦根據2019年A股激勵計劃行使股票期權,發行了29,747股A股普通股。股份回購及期權行使後,公司於2024年3月26日的已發行股份總數為2,546,239,690股。根據香港聯合交易所有限公司證券上市規則,公司已完成相關披露要求,並確認所有交易均獲董事會批准,並符合相關法律規定。
Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. repurchased a total of 3,359,666 shares of A-shares ordinary shares through the Shanghai Stock Exchange from 8 to 26 March 2024, representing approximately 0.13% of the company's issued shares. The Company's share repurchase price ranges from RMB 47.5 to RMB 57.32, and on March 26, 2024 it repurchased 422,000 shares for a total amount of RMB 20,045,895. In addition, on the same day, the company issued 29,747 shares of A-share ordinary shares under the 2019 A-share incentive plan. Following the share repurchase and exercise of options, the total number of shares issued by the Company as of March 26, 2024 was 2,546,239,690 shares. Pursuant to the Listing Rules of the Hong Kong Stock Exchange Limited, the Company has completed the relevant disclosure requirements and confirmed that all transactions have been approved by the Board of Directors and comply with the relevant legal requirements.
Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. repurchased a total of 3,359,666 shares of A-shares ordinary shares through the Shanghai Stock Exchange from 8 to 26 March 2024, representing approximately 0.13% of the company's issued shares. The Company's share repurchase price ranges from RMB 47.5 to RMB 57.32, and on March 26, 2024 it repurchased 422,000 shares for a total amount of RMB 20,045,895. In addition, on the same day, the company issued 29,747 shares of A-share ordinary shares under the 2019 A-share incentive plan. Following the share repurchase and exercise of options, the total number of shares issued by the Company as of March 26, 2024 was 2,546,239,690 shares. Pursuant to the Listing Rules of the Hong Kong Stock Exchange Limited, the Company has completed the relevant disclosure requirements and confirmed that all transactions have been approved by the Board of Directors and comply with the relevant legal requirements.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more